Abstract

Ceftaroline is a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). A collection of 17 clinical and veterinary mecC-positive MRSA isolates was tested to evaluate the in vitro efficacy of ceftaroline against recently emerged mecC-MRSA isolates. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of ceftaroline for the 17 isolates were determined by broth microdilution using the methodology and interpretive criteria of the Clinical and Laboratory Standards Institute (CLSI). Additional susceptibility tests were performed using ceftaroline M.I.C. Evaluator (M.I.C.E.(TM)) strips. All isolates showed susceptibility according to CLSI breakpoints, with MICs of ceftaroline ranging from 0.125 mg/L to 0.25 mg/L. MBCs were identical or up to a twofold dilution step higher. In conclusion, all tested isolates, from various sources and belonging to several clonal complexes (CCs), but predominantly to CC130, were found to be susceptible to ceftaroline. Ceftaroline could thus be an option for the treatment of mecC-MRSA infections. (C) 2016 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Keywords

Staphylococcus aureus; MRSA; mecC; SCCmec XI; Ceftaroline

Published in

Journal of Global Antimicrobial Resistance
2016, Volume: 5, pages: 3-6
Publisher: ELSEVIER SCI LTD

SLU Authors

• Gavier Widén, Dolores

  • Department of Animal Biosciences, Swedish University of Agricultural Sciences
    
  • National Veterinary Institute (SVA)

Sustainable Development Goals

Ensure healthy lives and promote well-being for all at all ages


UKÄ Subject classification

Pathobiology


Publication identifier

DOI: https://doi.org/10.1016/j.jgar.2016.01.006

Permanent link to this page (URI)

https://res.slu.se/id/publ/83272